Bladder cancer is a disease in which abnormal cells grow uncontrollably in the lining of the bladder. It is the sixth most common cancer in the United States, with an estimated 84,530 new cases expected in 2026. Men are diagnosed roughly three times more often than women. The good news: most bladder cancers are caught early, when they are still confined to the bladder’s inner lining and highly treatable.
Types of Bladder Cancer
More than 90% of bladder cancers are urothelial carcinomas, meaning they start in the specialized cells that line the inside of the bladder. These cells stretch and compress as the bladder fills and empties, and their constant exposure to whatever passes through urine makes them vulnerable to cancer-causing substances.
The remaining cases include squamous cell carcinoma, adenocarcinoma, and small cell carcinoma. These rarer types tend to behave differently and sometimes require different treatment approaches, but the initial workup is similar for all of them.
Symptoms and Early Warning Signs
Blood in the urine is the most common first sign, showing up in about 80% of people eventually diagnosed with bladder cancer. It is typically painless, visible to the naked eye, and comes and goes, which can trick people into thinking the problem has resolved on its own. Sometimes the bleeding is only detectable under a microscope during a routine urinalysis.
About 20% of patients experience irritative urinary symptoms instead of or alongside blood in the urine. These include a sudden, strong need to urinate, urinating more frequently than usual, or pain during urination. Because these symptoms overlap with urinary tract infections and other common conditions, they are easy to dismiss. Persistent irritative symptoms that don’t improve with standard UTI treatment deserve further evaluation.
What Causes Bladder Cancer
Cigarette smoking is the single biggest risk factor. Chemicals from tobacco smoke are absorbed into the blood, filtered by the kidneys, and concentrated in urine, where they sit in direct contact with the bladder wall for hours at a time. Quitting reduces the risk, though it takes years for the elevated risk to drop significantly.
Workplace chemical exposure is the second major contributor. People who work with paints, dyes, metals, or petroleum products face higher rates of bladder cancer, sometimes decades after their exposure ended. Other established risk factors include:
- Family history of bladder cancer or certain inherited gene changes
- Prior pelvic radiation or treatment with specific chemotherapy drugs
- Chronic bladder irritation from long-term catheter use or, in parts of Africa and the Middle East, a parasitic infection called schistosomiasis
- Arsenic in drinking water, particularly from private wells
How Bladder Cancer Is Diagnosed
Cystoscopy is the gold standard. A thin, lighted scope is passed through the urethra into the bladder, giving the doctor a direct view of the bladder wall. If anything suspicious appears, a tissue sample is taken during the same procedure. The whole process typically takes 15 to 30 minutes and can often be done in an office setting under local anesthesia.
Urine cytology, where a urine sample is examined under a microscope for abnormal cells, is usually done alongside cystoscopy. Cytology is very good at catching high-grade cancers (specificity above 90%) but can miss low-grade tumors. Newer urine-based tests exist that look for specific proteins or genetic markers, and some are FDA-approved, but none have replaced the combination of cystoscopy and cytology as the standard approach.
Stages of Bladder Cancer
The single most important distinction in bladder cancer is whether it has grown into the muscle wall of the bladder. This divides the disease into two broad categories with very different treatment paths and outlooks.
Non-Muscle-Invasive (Stages 0 and I)
Most bladder cancers are diagnosed at this stage, when the tumor is still limited to the bladder’s inner lining or the thin connective tissue just beneath it. The cancer has not reached the thick muscle layer that allows the bladder to contract. About 34% of all bladder cancers are diagnosed while still localized, and the five-year relative survival rate for these cases is 73%.
Muscle-Invasive (Stages II and III)
Stage II means the cancer has grown into the muscle wall itself. By stage III, it has pushed through the muscle and into the surrounding fat layer or nearby organs such as the prostate, uterus, or vagina, or has reached nearby lymph nodes. Seven percent of cases are diagnosed at this regional stage, and the five-year survival rate drops to about 42%.
Advanced and Metastatic (Stage IV)
Stage IV cancer has spread to the pelvic or abdominal wall, to distant lymph nodes, or to other organs like the lungs, liver, or bones. About 6% of bladder cancers are found at this stage, and the five-year relative survival rate is roughly 10%.
Treatment for Early-Stage Bladder Cancer
The first step for non-muscle-invasive bladder cancer is a procedure called transurethral resection, or TUR. A surgeon inserts a tool through the urethra and scrapes or burns away the tumor from the bladder wall. There is no external incision, and most people go home the same day or the next.
Because early-stage bladder cancer has a high tendency to come back, most people receive additional treatment directly into the bladder after surgery. This involves placing a liquid medication through a catheter so it bathes the bladder lining. The two main options are a form of immunotherapy that uses a weakened bacterium (BCG) to provoke the immune system into attacking remaining cancer cells, or chemotherapy drugs. BCG is generally preferred for intermediate and high-risk tumors.
Depending on how aggressive the cancer looks under a microscope, maintenance BCG therapy may continue on a schedule for up to three years. For very high-risk cases, such as those with multiple tumors or a flat, high-grade pattern called carcinoma in situ, removing part or all of the bladder may be recommended upfront rather than relying on BCG alone.
Treatment for Muscle-Invasive Disease
When cancer has reached the muscle wall, the two primary options are surgical removal of the entire bladder (radical cystectomy) or a combination of radiation and chemotherapy aimed at preserving the bladder.
Radical cystectomy involves removing the bladder along with surrounding tissues and nearby lymph nodes. In men, the prostate is also removed. In women, the uterus and part of the vagina are typically taken as well. After the bladder is gone, surgeons create a new way for urine to leave the body, either through a small opening in the abdomen that drains into an external pouch or by fashioning a new internal reservoir from a segment of intestine.
Chemotherapy containing cisplatin is often given before surgery. This pre-surgical (neoadjuvant) approach has been shown to improve long-term survival compared to surgery alone. After surgery, if the cancer carries a high risk of returning, immunotherapy may be offered to help the immune system patrol for stray cancer cells.
For people who cannot have or prefer not to undergo major surgery, radiation combined with chemotherapy can sometimes achieve similar cancer control while keeping the bladder intact. This bladder-sparing approach requires close monitoring afterward.
Treatment for Metastatic Bladder Cancer
When bladder cancer has spread to distant sites, the focus shifts to systemic therapies that travel throughout the body. Platinum-based chemotherapy has long been the first-line treatment, but the landscape has changed substantially in recent years.
Immune checkpoint inhibitors, drugs that help the immune system recognize and attack cancer cells, now play a central role. Newer treatments called antibody-drug conjugates deliver chemotherapy directly to cancer cells by attaching it to an antibody that seeks out a protein on the tumor’s surface. One such drug, enfortumab vedotin, received FDA approval in 2019 and has shown particularly strong results when combined with an immunotherapy drug, achieving tumor shrinkage in nearly 65% of patients who were not candidates for cisplatin-based chemotherapy. Another antibody-drug conjugate, sacituzumab govitecan, has shown a 27% response rate in patients who had already been through multiple prior treatments.
Long-Term Monitoring
Bladder cancer recurs more often than almost any other solid tumor, which means long-term surveillance is a defining part of the experience. The first follow-up cystoscopy after initial surgery happens at three months and is considered one of the strongest predictors of how the disease will behave going forward.
For low-risk tumors, cystoscopies are typically performed every three to six months for the first two years, then annually. After five years without recurrence, the risk of the cancer returning drops considerably, and some patients may be able to reduce or stop surveillance. For high-risk tumors, monitoring with cystoscopy and urine testing continues for life, because recurrences have been documented even ten or more years after what appeared to be a complete response.
A small percentage of patients with high-risk non-muscle-invasive bladder cancer, roughly 2% to 4%, will eventually develop cancer in the upper urinary tract (the kidneys or ureters), so periodic imaging of those areas is also part of long-term follow-up.